【レポートの概要（一部）】
1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. An Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction to Dermatology
2.2.1 The Structure of Skin, Hair, and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.3.1 Acne: The Most Common Skin Disease
2.3.1.1 Acne: Epidemiology
2.3.1.2 Acne: Causes and Pathogenesis
2.3.1.3 Acne: Treatment
2.3.2 Dermatitis: Inflammation of the Skin
2.3.2.1 Atopic Dermatitis
2.3.2.2 Contact Dermatitis
2.3.2.3 Seborrhoeic Dermatitis
2.3.2.4 Nummular Dermatitis
2.3.2.5 Perioral Dermatitis
2.3.3 Psoriasis: A Complex Multi-factorial Disease
2.3.4 Rosacea: Vascular Instability
2.3.5 Alopecia: Excessive Shedding Of Hair
2.4 Skin Infections: A Serious Healthcare Threat
2.4.1 Bacterial Skin Infections
2.4.2 Fungal Skin Infections
2.4.3 Viral Skin Infections
2.5 Common Skin Treatments
2.5.1 Creams and Semisolid Emulsions
2.5.2 Ointments
2.5.3 Lotions
2.5.4 Solutions
2.5.5 Occlusive Therapy
2.5.6 Cleansing Agents
2.5.7 Powders and Hydrophilic Polymer
2.5.8 Anti-Infective Agents
2.5.9 Anti-Inflammatory Agents
2.6 Phases of Clinical Trials
2.7 Dermatological Drugs: Market Definition in this Report
3. The Global Dermatological Drugs Market, 2016-2026
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation of the Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market in 2015
3.4 The Global Dermatological Drugs Market: Market Forecast 2016-2026
3.5 Dermatological Drugs: Changing Market Shares by Sector 2016-2026
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2016-2026
4.1 Psoriasis Treatments: The Dominance of Biologics
4.1.1 Leading Products in the Psoriasis Drugs Market, 2015
4.2 Psoriasis: Market Trends and Developments, 2016
4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
4.2.3 The Disadvantages of Biologics in Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2016-2026
4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2015-2026
4.4 Leading Drugs Used in the Treatment of Psoriasis
4.4.1 Humira (adalimumab) – AbbVie
4.4.1.1 Humira: Historical Sales Analysis, 2010-2015
4.4.1.2 Humira: Sales Forecast 2016-2026
4.4.1.3 Future Prospects for Biosimilar Versions of Humira
4.4.2 Stelara (ustekinumab) – Johnson & Johnson
4.4.2.1 Stelara: Historical Sales Analysis, 2010-2014
4.4.2.2 Stelara: Sales Forecast 2016-2026
4.4.2.3 Intensifying Competition for Stelara
4.4.3 Enbrel (etanercept) – Amgen/ Pfizer/ Takeda
4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
4.4.3.2 Enbrel: Historical Sales Analysis, 2008-2015
4.4.3.2 Enbrel: Patent Expiries and Potential Competition, 2016-2026
4.4.3.4 Enbrel: Sales Forecast 2016-2026
4.4.3.5 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
4.4.3.6 Competition from Other Drugs
4.4.3.7 Biosimilar Competition for Enbrel
4.4.4 Remicade (infliximab) – Johnson & Johnson
4.4.4.1 Remicade: Historical Sales Analysis, 2010-2015
4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2016-2026
4.4.4.3 Remicade: Sales Forecast 2016-2026
4.4.5 Taltz (ixekizumab) – Eli Lily
4.4.5.1 Taltz: Sales Forecast 2016-2026
4.4.6 Otezla (apremilast) – Celgene
4.4.6.1 Otezla: Sales Forecast 2016-2026
4.4.7 Cosentyx (secukinumab) – Novartis
4.4.7.1 Cosentyx: Sales Forecast 2016-2026
4.4.8 Other Psoriasis Drugs
4.4.8.1 Cimzia (certolizumab) – UCB
4.4.8.2 Sorilux (calcipotriene foam) – GSK
4.4.8.3 Other Psoriasis Drugs: Sales Forecast 2016-2026
4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2016-2026
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products in the Skin Infection Drugs Market, 2015
5.2 Skin Infection Drugs: Market Forecast 2016-2026
5.2.1 Skin Infection Drugs: Changing Market Shares by Leading Drugs 2016-2026
5.3 Leading Drugs Used in the Treatment of Skin Infections
5.3.1 Cubicin (daptomycin) – Cubist Pharmaceuticals/ Merck & Co
5.3.2 Acquisition By Merck & Co
5.3.3 Generic Competition For Cubicin
5.3.4 Cubicin: Sales Forecast 2016-2026
5.3.5 Lifecycle Management Strategies for Cubicin
5.4 Zyvox (linezolid) – Pfizer
5.4.1 Zyvox: Historical Sales Analysis, 2010-2014
5.4.2 Zyvox: Sales Forecast 2016-2026
5.4.3 The Threats to Zyvox Sales from Competing New Drugs
5.5 Canesten (clotrimazole) – Bayer
5.5.1 Canesten: Historical Sales Analysis, 2011-2014
5.5.2 Canesten: Sales Forecast 2016-2026
5.6 Valtrex (valaciclovir) – GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2016-2026
5.7 Bactroban (mupirocin) – GSK
5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
5.7.2 Bactroban: Sales Forecast 2015-2026
5.8 Lamisil (terbinafine) – Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2016-2026
5.9 Other Skin Infection Drugs
5.9.1 Dalvance (dalbavancin) – Durata Therapeutics
5.9.2 Jublia (efinaconazole) – Valeant
5.9.3 Kerydin (tavaborole) – Anacor
5.9.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.9.5 Zovirax (acyclovir) – Valeant/GSK
5.9.5.1 Valeant Acquires Zovirax In US And Canada
5.9.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic
5.9.6 Other Skin Infection Drugs: Sales Forecast 2016-2025
5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2016-2026
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products in the Acne Drugs Market, 2015
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise of Combination Therapies in Acne Treatment
6.2.2 Oral Contraceptives in Treating Acne
6.2.3 The Threat of Generic Competition in the Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2026
6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2015-2026
6.4 Leading Drugs in the Acne Drugs Market
6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.4.1.1 Epiduo: Sales Forecast 2016-2026
6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
6.4.1.3 Paediatric Approval for Epiduo
6.4.2 Solodyn (minocycline) – Valeant
6.4.2.1 Solodyn: Sales Forecast 2016-2026
6.4.2.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.4.2.3 Impax And Medicis Collaborating On Advanced Solodyn
6.4.2.4 Medicis And Lupin Settle
6.4.3 Claravis (isotretinoin) – Teva
6.4.3.1 Claravis: Sales Forecast 2016-2026
6.4.4 Aczone (dapsone) – Allergan
6.4.4.1 Aczone: Sales Forecast 2016-2026
6.4.5 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.4.5.1 Recent Generic Competition to Differin
6.4.5.2 Differin: Sales Forecast 2016-2026
6.4.5.3 Adapalene Gel to be Available OTC in the US
6.4.5.4 Federal Circuit Court Invalidates Differin Patents
6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma
6.4.6.1 Absorica/Epuris: Sales Forecast 2016-2025
6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.4.7.1 Valeant’s Patent Settlement with Actavis Over Ziana
6.4.7.2 Ziana: Sales Forecast 2016-2026
6.4.8 Doryx (doxycycline) – Actavis/ Mayne Pharma
6.4.8.1 Lifecycle Management Strategies for Doryx
6.4.8.2 Divestment Agreement with Mayne Pharma
6.4.8.3 Generic Competition for Doryx
6.4.8.4 Doryx: Sales Forecast 2016-2026
6.4.9 Other Acne Drugs
6.4.9.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.4.9.2 Amnesteem (isotretinoin) – Mylan
6.4.9.2.1 Amnesteem: Financial Analysis
6.4.9.3 Diane (cyproterone/ethinyl estradiol) – Bayer
6.4.9.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.4.9.5 Veltin (tretinoin/clindamycin) – GSK
6.4.9.6 Other Acne Drugs: Sales Forecast 2016-2026
6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2016-2026
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products in the Dermatitis Drugs Market, 2015
7.2 Dermatitis Drugs: Market Forecast 2016-2026
7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2016-2026
7.3 Leading Drugs in the Dermatitis Drugs Market
7.3.1 Bepanthen (dexpanthenol)/ Bepanthol – Bayer
7.3.1.1 Bepanthen: Sales Forecast 2016-2026
7.3.2 Elocon (mometasone) – Merck & Co
7.3.2.1 Elocon: Sales Forecast 2016-2026
7.3.3 Protopic (tacrolimus) – LEO Pharma
7.3.3.1 Protopic Benefits from Expanded Indication
7.3.3.2 Generic Competition For Protopic
7.3.3.3 Protopic: Sales Forecast 2016-2026
7.3.4 Dermovate -GSK
7.3.4.1 Dermovate: Sales Forecast 2016-2026
7.3.5 Other Dermatitis Drugs: Sales Forecast 2016-2026
7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets for Dermatological Drugs, 2016-2026
8.1 The Dermatological Drugs Market by Region
8.1.1 The Global Distribution of Dermatological Drugs in 2015
8.2 Leading National Markets: Forecast 2016-2026
8.2.1 Changing Market Shares by Region, 2015-2026
8.3 Regional Dermatological Drugs Markets: Analysis and Forecasts, 2015-2026
8.3.1 United States: The Largest Dermatological Drugs Market
8.3.1.1 The Impact of an Expanding Medicare Coverage
8.3.1.2 Legislative Environment Stimulating Biosimilars Market?
8.3.1.3 US Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2 The EU5 Markets: Growth Expected in Each Country
8.3.2.1 EU5 Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2.1.1 EU5 Markets: Changing Market Shares by Country, 2015-2026
8.3.2.2 Germany
8.3.2.2.1 German Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2.3 France
8.3.2.3.1 French Dermatological Drugs Market Forecast 2016-2026
8.3.2.4 UK
8.3.2.4.1 UK Dermatological Drugs Market Forecast 2016-2026
8.3.2.5 Italy
8.3.2.5.1 Italian Dermatological Drugs Market Forecast 2016-2026
8.3.2.6 Spain
8.3.2.6.1 Spanish Dermatological Drugs Market Forecast 2016-2026
8.3.3 Japan
8.3.3.1 The Cost of Treatment in Japan
8.3.3.2 Japanese Pharmaceutical Industry Regulatory Reform
8.3.3.3 Japanese Dermatological Drugs Market Forecast 2016-2026
8.3.4 China
8.3.4.1 Expansion of Healthcare Coverage and Reimbursement in China
8.3.4.2 Improving Public Perception of Dermatology in China
8.4.3.3 Price Controls and the Anhui Model
8.3.4.4 Chinese Dermatological Drugs Market Forecast 2016-2026
8.3.5 India
8.3.5.1 The Effects of the Drug Prices Control Order of 2013
8.3.5.2 India’s Expansion of Healthcare Provision
8.3.5.3 Indian Dermatological Drugs Market Forecast 2016-2026
8.3.6 Brazil
8.3.6.1 The Growth in Brazil’s Healthcare Landscape
8.3.6.2 Clearer Access to Medicines in Brazil
8.3.6.3 Brazilian Dermatological Drugs Market Forecast 2016-2026
8.3.7 Russia
8.3.7.1 Pharma2020 Strategy – Healthcare and Industry Reform
8.3.7.2 Russian Dermatological Drugs Market Forecast 2016-2026
8.3.8 Rest of the World
8.3.8.1 The Rest of the World Dermatological Drugs Market Forecast 2016-2026
9. Leading Companies in the Dermatological Drugs Market, 2016-2026
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2016
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition of Galderma
9.2.2.2 Approval and Launch of Soolantra for Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson & Johnson: Dermatological Drug Development
Pipeline, 2016
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2016
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2016
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2016
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2016
9.6.2 Pfizer: Dermatological Drugs Development Pipeline, 2016
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2016
9.7.2 LEO Pharma: Dermatological Drugs Development Pipeline, 2016
10. Dermatological Drugs: Research and Development Pipeline, 2016-2026
10.1 Innovative Products Currently in Development Will Drive Growth
10.1.1 New Technology in R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms and Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2016
10.2.1 Psoriasis Drugs in Phase 3 Development or Regulatory Approval Stage
10.2.1.1 AMG 827 (brodalumab) – AstraZeneca/ LEO Pharma
10.2.1.2 CF101 (Piclidenoson) – Can-Fite BioPharma
10.2.1.3 CNTO 1959 (guselkumab) – MorphoSys/ Janssen
10.2.1.4 LAS41008 (dimethyl fumarate) – Almirall
10.2.1.5 MK-3222/SCH 900222 (tildrakizumab) – Merck/Sun Pharma
10.2.2 Psoriasis Drugs in Phase 2 Development
10.2.2.1 LY3009104 (baricitinib) – Incyte/ Eli Lilly
10.2.2.2 PH-10 (Rose Bengal) – Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2016
10.3.1 Drugs in Phase 3 Development for Skin Infections
10.3.1.1 Baxdela (delafloxacin) – Melinta Pharmaceuticals
10.3.1.2 NB-001 – NanoBio Corporation
10.3.1.3 Luliconazole – Topica Pharmaceuticals
10.3.2 Drugs in Phase 2 Development for Skin Infections
10.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
10.4 Acne Drugs Development Pipeline, 2016
10.4.1 Drugs in Phase 3 Development for Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) – GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) – Photocure
10.4.2 Drugs in Phase 2 Development for Acne
10.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
10.4.4 A Possible Vaccine for Acne
10.5 Dermatitis Drugs Development Pipeline, 2016
10.5.1 Drugs in Phase 3 Development for Dermatitis
10.5.1.1 Toctino (alitretinoin) – GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) – Regeneron/ Sanofi
10.5.2 Drugs in Phase 2 Development for Dermatitis
10.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2016
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) – Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) – Biofrontera
10.6.1.3 Mirvaso (brimonidine) – Galderma
10.6.1.4 Picato (ingenol mebutate) – LEO Pharma
10.6.1.5 Xolair (omalizumab) – Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2016
10.6.2.1 CD5024 (ivermectin) – Galderma
10.6.2.2 SR-T100 gel (Solanum incanum extract) – G&E Herbal Biotechnology
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2016
11. Qualitative Analysis of the Dermatological Drugs Market, 2016-2026
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need in Dermatology
11.2.1.2 A Healthy Pipeline of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy and Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge to Treatment Design
11.2.2.3 Impending Patent Expiries and the Challenges Posed by Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors in Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances in Genomics
11.2.3.3 Advances in Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement and Payment Approvals
11.2.4.2 The Rising Cost of Research and Development
11.2.4.3 Downward Pressures on Drug Prices
11.3 Porter’s Five Force Analysis of the Global Dermatological Drugs Market, 2016-2026
11.3.1 Threat of New Entrants
11.3.2 Threat of Substitutes
11.3.3 Rivalry among Competitors
11.3.4 Power of Buyers
11.3.5 Power of Suppliers
12. Conclusions
12.1 Overview of Current Market Conditions and Market Forecast, 2015-2026
12.2 Leading Sectors in Dermatological Drugs in 2015
12.3 Leading Regions in the Dermatological Drugs Market in 2015
12.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2016-2026
12.5 What Does The Future Hold For Dermatological Drugs?
13. Glossary
【レポート販売概要】
■ タイトル：皮膚科治療薬の世界市場予測2016-2026■ 英文：Dermatological Drugs Market Forecast 2016-2026
■ 発行日：2016年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN81920
■ 調査対象地域：グローバル
- 航空用塗料（コーティング）の世界市場：商用航空、軍事航空、ゼネラル・アビエーション用塗料The report covers the global aerospace coatings market and further divides the market on the basis of end-user industry, user type, and region. The market data for both end-user industry and user types is given with respect to volume (thousand tons) and value ($million). The global market size, in terms of value, of aerospace coatings was estimated to be $2,109.64 million in 2013 and is projected …
- グローバル香料市場におけるM&A動向（2014年3月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global fragrances market during March 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global fragrances market throughout the month. Additionally, the report provides an overview of all the part …
- 海水淡水化用ポンプの世界市場：遠心ポンプ、容積式ポンプAbout Water Desalination Pumps Pumps are vital for the optimum operation of water desalination plants. Well-designed and properly operating desalination plants require precise pumps. Notably, pumps constitute a relatively smaller part of a desalination plant's total capital expenditure. However, they play a critical role in determining the productivity and efficiency of a system, and return on inv …
- 防護服の世界市場：材料種類別（アラミド＆ブレンド、ポリオレフィン＆ブレンド、ポリベンズイミダゾール、綿繊維、積層ポリエステル、その他）、用途別（熱、機械、化学、放射線、その他）、エンドユーザー産業別（石油＆ガス、建設＆製造、医薬品、法執行＆軍事、消防、その他）Global Protective Clothing Market was valued at $8.0 billion in 2018, and is expected to reach $12.9 billion by 2026, supported by a CAGR of 6.2% during the forecast period 2019 to 2026. Innovation in textile industry and launch of new fibers have transformed the familiar functions of conventional textile to the advance textile industry. Protective clothing are manufactured using traditional texti …
- セルベースアッセイの世界市場：セルベースアッセイ装置/消耗品/サービスCellular testing for pharmaceuticals – how to discover that technology’s commercial potential What’s the future of technologies for screening cells? Now discover those technological and commercial predictions from 2015. Stay ahead there for data, benefiting your influence. For those medical tests, you explore sales results, R&D, opportunities and revenue forecasts. That new report by visiongain sh …
- 世界の潜水艦市場（2014-2024）：トレンド、進歩、課題Synopsis This report offers readers insights into technological developments in the Submarine market, as well as detailed analysis of the changing preferences of military forces around the world. It also identifies the current trends in the changing industry structure and the challenges faced by industry participants. Summary Technological Developments in the global Submarine include: • Shift to I …
- 冷蔵・冷凍輸送の世界市場2016-2020About Refrigerated Transportation Refrigerated transportation is used to supply customers with safe and high-quality perishable goods. These perishable goods can be perishable food products, pharmaceuticals, or others like flowers and chemical products. This type of transportation is carried out via roadways, seaways, and airways. Transportation by airways is used mainly by the pharmaceutical indu …
- 潤滑剤の世界市場：鉱油潤滑剤、合成潤滑剤、生物由来潤滑剤、グリースThe global lubricants market is projected to reach USD 166.59 Billion by 2021, registering a CAGR of 2.4% between 2016 and 2021. This rapid growth in the automotive industry in Asia-Pacific is a key driver of the lubricants market. More than 60% of lubricants are consumed by the transportation application segment in 2015. Also, the rapid growth of various manufacturing industry in emerging nations …
- 外側上顆炎治療の世界市場2019-2023About this market Lateral epicondylitis is common in people who participate in physical activities such as racket sports, hockey, canoeing, weight-lifting, wrestling, rowing, and swimming. Moreover, it can also occur in people who apply more pressure on extensor carpi radialis brevis and longus muscles of the forearm, as a part of their work. These people observe severe and long-term pain around t …
- 医療・科学デバイス用LEDの世界市場This report by ElectroniCast Consultants provides the research findings of our study of the worldwide consumption of packaged Light Emitting Diodes (LEDs), in Scientific and Medical Devices. This report provides global market data covering the years 2014-2024. The market data are segmented into the following geographic regions, plus a Global summary: • North, Central and South America (America) • …
- Cubic Energy, Inc.社の石油・ガス開発・生産動向及びコスト分析（2013年）Cubic Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary Cubic Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
- マーケティング自動化ソフトウェアの世界市場2017-2021About Marketing Automation Software Marketing automation software is mainly used to streamline, schedule, segment, and track marketing campaigns. The software reduces the number of repetitive tasks associated with the conventional marketing processes and improves their overall efficiency. It also provides features such as e-mail marketing, campaign creation and management, data collection and stor …
- ボディードライヤーの世界市場：種類別（壁掛け式、床置き式）、エンドユーズ別（住宅、商業）The body dryer market size was valued at $2,641.5 thousand in 2018, and is projected to reach $3,424.0 thousand by 2026, growing at a CAGR of 3.4% from 2019 to 2026. Body dryers are air blowing electric appliances (similar to hand dryer or hair dryer) used in drying an individual’s complete body after bathing or swimming, substituting the use of a towel. The appliance is available in two variants, …
- クラウド・アプリケーション・マーケットプレイス2015 – 2020Cloud is moving beyond computing and storage and into an entirely new realm of communications, applications, content and applications. There are profound changes that are realized with this transformation, which are impacting infrastructure, services, companies, solutions, and business models. Cloud Application Marketplace 2015 - 2020 informs decision makers and provides an understanding of the ke …
- 産業廃棄物管理の世界市場（～2019）This report estimates the industrial waste management market in terms of value. The global industrial waste management market is segmented based on their services which include collection, recycling, incineration, and landfill. The market is further segmented on the basis of regions such as Asia-Pacific, Europe, Middle East & Africa, and Americas. This has been further split into major countries f …
